Brookline downgraded Verrica Pharmaceuticals to Hold from Buy and suspended the firm’s price target following what it calls a “major restructuring.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals to reduce number of sales territories to 35 from 80
- Verrica Pharmaceuticals Finalizes Agreements with Former Officer
- Verrica Pharmaceuticals CCO Joe Bonaccorso Resigns, Assumes Consulting Role
- Biotech Alert: Searches spiking for these stocks today
- Verrica Pharmaceuticals Unveils Updated Corporate Strategy